Table 3.
Clinical performance of Lumipulse assays in a validation cohort
| Controls (n = 10) | AD (n = 20) | Total (n = 30) | |
|---|---|---|---|
| Gender (M/F) | 3/7 | 9/11 | 12/18 |
| Age (years) | 58.2 ± 10.7 | 67.2 ± 6.2 | 64.2 ± 9.7 |
| Correctly classified | |||
| Lumipulse | |||
| Aβ42 | 10 (100%) | 15 (75%) | 25 (83%) |
| t-Tau | 10 (100%) | 18 (90%) | 28 (93%) |
| p-Tau | 10 (100%) | 17 (85%) | 27 (90%) |
| Aβ42/Aβ40 | 10 (100%) | 19 (95%) | 29 (97%) |
| Aβ42/t-Tau | 10 (100%) | 19 (95%) | 29 (97%) |
| Aβ42/p-Tau | 10 (100%) | 19 (95%) | 29 (97%) |
Data are expressed as mean ± SD (age), as number of males (M) and females (F), and as the number (%) of correctly classified samples according to the previously determined cut-offs for Lumipulse assays